Danish Marine and Shipping Stock News

Lollands Bank comes into this earnings season with a stock that has been quietly grinding higher, up about 2.1% over the past week and 2.5% over three months, while trading on a modest P/E of 10.4x. The headline from Q2 is simple: profitability is the story. Net profit margins over the last year sit at 30.8% compared with 29.5% a year earlier, and earnings have risen 3.3% over that period. For a regional bank, that margin profile is the key tension between the muted share price moves and what...

Novozymes stock went into today on a strong run, with the share price up about 17% over the past three months and trading on a rich P/E near 45x. That kind of optimism sets a high bar. The earnings headline is clear. Organic sales in the first half grew 8% with adjusted earnings before interest, tax, depreciation and amortization margin at 37.7%, and management lifted full year organic growth guidance to 7 to 8% with margin expected at the top of the 37 to 38% range. Is Novozymes at 45x P/E a...

Carlsberg stock has drifted lower in recent weeks, with the share price down about 7% over the past month even as H1 results landed with solid headline growth. The earnings story that matters most is not the revenue print. It is the squeeze on profitability that shows up in a trailing net margin of 7.1% compared with 8.1% a year earlier. Short term traders are reacting to the chart. Long term holders are more likely focused on a company that still carries a premium P/E multiple and high debt,...

Kreditbanken entered this earnings day with a strong equity story in the bank sector. The stock closed at DKK9,750 on 20 August after a solid run over the past quarter, and the fresh Q2 numbers show that the real action is in the income statement, not the chart. The headline is profitability. Net income for Q2 came in at DKK40.5 million on revenue of DKK101.6 million, while trailing 12 month net profit margin sits at 41%. For a stock trading on a trailing P/E of 11.1x, that combination of...

UIE went into this earnings print with a market profile that looked confused. The stock closed at DKK391 on 20 August, with a rich 21.1x P/E and yet a discount to a much higher cash flow valuation. That tension met a quarter where the headline story is profit quality rather than breakneck growth. Q2 2026 basic earnings per share landed at US$1.21 on net income of US$37.17m, a clean rebound from the loss in Q1. For you as an investor, the question now is how durable that margin recovery really...

The market has cooled on H. Lundbeck in recent months, with the stock down about 5% over 30 days and closing at DKK40.64 yesterday, even as the long term story has often centered on underappreciated value. Q2 2026 results land squarely in that expectation gap. Revenue of DKK6,463m and basic earnings per share of DKK1.16 tell a quieter quarterly story, yet the trailing P/E of 10.2x versus far higher industry averages and a discounted cash flow value estimate above DKK100 keep the valuation...

Rockwool stock has been treading water in recent weeks, roughly flat over one and three months. The latest earnings reminder is blunt: the company is still loss making on a trailing 12 month view, even as Q2 delivered €1,009m in revenue and €93m in net income from ongoing operations. The short term story is a stock that already trades on a rich sales multiple and sits well above a cited discounted cash flow value. The longer term question for you is whether the expected earnings recovery can...

Vestas Wind Systems (CPSE:VWS) drew investor attention after reporting second quarter 2026 earnings, with higher sales and net income than a year earlier, while also raising EBIT margin guidance for the full year. See our latest analysis for Vestas Wind Systems. The earnings release and raised margin outlook appear to be contributing to building momentum in Vestas Wind Systems, with a 30 day share price return of 15.19% and a 1 year total shareholder return of 56.28% from a lower base, even...

Coloplast stock closed at DKK441.8 on Wednesday, only modestly higher over the past week and month, even after investors digested a quarter that quietly reset the earnings narrative. The headline is a sharp profit rebound. Q3 basic earnings per share landed at 6.49 DKK with net income of DKK1,462m and total revenue of DKK7,355m. The market still carries the scar of the recent one off loss that dragged the trailing net margin down to 7.5%. Today’s calm price action suggests investors are...

Royal Unibrew stock has slipped over the past week and month, yet today’s earnings story is less gloomy than the recent price action suggests. The brewer delivered Q2 revenue of DKK 4,426m and basic earnings per share of DKK 11.1, with trailing earnings putting the stock on a P/E of 13x, below both peers and the wider European beverage group. The real tension for investors is between that value label and a business still nudged by modest growth and higher debt, which sets the stage for a...

Why Genmab’s latest earnings and guidance update matters for investors Genmab (CPSE:GMAB) reported second quarter 2026 results with higher sales but lower net income compared with a year earlier. The company also raised full year revenue guidance, giving investors an updated view of expected performance. See our latest analysis for Genmab. Genmab’s latest earnings release and raised revenue guidance have coincided with strong recent momentum, with a 30 day share price return of 12.57% and a...

As the European markets navigate a landscape marked by resilient economic data and geopolitical uncertainties, investors are increasingly looking towards diverse opportunities. Penny stocks, though an older term, continue to attract attention due to their potential for growth at lower price points. These smaller or newer companies can offer unique investment opportunities when backed by strong financials and solid fundamentals.

A week ago, Zealand Pharma A/S ( CPH:ZEAL ) came out with a strong set of second-quarter numbers that could potentially...

Jeudan earnings event puts focus on revenue and profit trends Jeudan (CPSE:JDAN) reported second quarter 2026 results that showed higher sales but lower net income and earnings per share compared with the same period in 2025. Investors now have fresh numbers to reassess the stock. See our latest analysis for Jeudan. Jeudan's latest earnings update comes as the stock trades at DKK204.0, with a 1-day share price return of 0.99% and a year-to-date share price gain of 3.55%. Over the same period,...

How NKT’s latest earnings and guidance update set the stage NKT (CPSE:NKT) reported second quarter 2026 earnings that were close to the prior year, alongside six month figures that showed similar stability in sales and net income. On the same day, the company also narrowed its 2026 revenue outlook to a range of €2.65b to €2.75b, compared with earlier guidance of €2.63b to €2.78b. This gave investors a more focused view of expected activity levels for the rest of the year. See our latest...

As the European market navigates a landscape marked by resilient economic data and geopolitical uncertainties, the STOXX Europe 600 Index recently closed slightly lower, reflecting investor caution amid these mixed signals. Despite these challenges, opportunities may exist for investors seeking undervalued stocks that could benefit from current sector shifts and regional economic resilience. In this context, identifying stocks trading below their estimated value can be particularly appealing...

A.P. Møller - Mærsk A/S ( CPH:MAERSK B ) just released its quarterly report and things are looking bullish. A.P. Møller...

Shareholders of DFDS A/S ( CPH:DFDS ) will be pleased this week, given that the stock price is up 19% to kr.155...

It's been a good week for Solar A/S ( CPH:SOLAR B ) shareholders, because the company has just released its latest...

Aktieselskabet Schouw went into this report with the stock at DKK680 after a solid run over the past month, and the market is now weighing whether that optimism matches the earnings reality. The headline is clear: Q2 2026 delivered a sharp jump in profitability, with basic earnings per share at DKK14.18 and net income at DKK321m, both well ahead of Q1. In addition, management lifted full year revenue and EBITDA guidance for 2026, which puts the focus firmly on whether this improvement looks...

Global bond yields have pushed higher as inflation expectations adjust, which has pressured long term rates and made dependable cash flows more valuable in pricing models. When markets focus on macro swings, stocks with solid projected cash generation that also trade below fair value can get overlooked. This article highlights 3 stocks from the Undervalued Stocks Based On Cash Flows screener that stand out on this theme. The 3 stocks highlighted below are just a small sample, since the full...

FLSmidth (CPSE:FLS) stock is back in focus after the company named Petri Virrankoski as President of its Service Business Line, with a planned 2027 start. The appointment underscores attention on the service segment. See our latest analysis for FLSmidth. The leadership news comes at a time when FLSmidth’s recent momentum has been positive. The 1 month share price return is 6.38% and the 1 year total shareholder return is 27.11%. In addition, the 5 year total shareholder return of 155.07%...

Novo Nordisk (CPSE:NOVO B) has entered an AI-focused partnership with H1 to support clinical trial operations. The collaboration uses H1's proprietary AI-ready data and clinical development workflows to support drug development. The agreement is aimed at improving clinical trial design, execution and site or investigator selection through data driven insights. This kind of AI partnership in drug development sits within a wider shift toward digital and data infrastructure. It is worth...

Novozymes (CPSE:NSIS B) drew fresh attention on 12 August 2026 after Novonesis launched Optiva Triticum, a biosolution designed to give pasta producers more flexibility in wheat sourcing while preserving texture and firmness. See our latest analysis for Novozymes. At a share price of DKK424.6, Novozymes has seen a 12.27% 90 day share price return and a 49.03% three year total shareholder return. This may point to momentum that product launches like Optiva Triticum may be influencing as...